RestructuringAug 5, 2026, 04:14 PM
Emergent BioSolutions Restructures, Cuts 93 Jobs; Q2 Revenue Up 66%
AI Summary
Emergent BioSolutions announced a significant organizational restructuring plan, including a reduction of approximately 93 employees, elimination of 21 vacant positions, and closure of wet laboratories, expected to yield $40 million in annualized savings. Concurrently, the company reported Q2 2026 total revenues of $234.3 million (up 66%) but a net loss of $180.2 million due to a $191.3 million non-cash impairment charge on its NARCAN® asset group. The Chief Medical Officer, Head of R&D, Simon Lowry, will depart, and Stephanie Duatschek will assume the role of Executive Vice President, Chief Growth Officer.
Key Highlights
- Organizational restructuring to reduce workforce by 93 employees and eliminate 21 vacant positions.
- Expected annualized savings of approximately $40 million from restructuring.
- Estimated restructuring charges of $10 million to $11.5 million, primarily in H2 2026.
- Q2 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year.
- Q2 2026 Net Loss of $180.2 million, worsening 1,402% due to $191.3 million impairment charge.
- Q2 2026 Adjusted Net Income of $30.9 million, improved 134% versus prior year.
- Simon Lowry, Chief Medical Officer, Head of R&D, to depart effective August 19, 2026.
- Stephanie Duatschek appointed Executive Vice President, Chief Growth Officer.
Price Impact
More from EBS